Objective: To evaluate dosing patterns, demographic characteristics, and safety outcomes in patients with advanced Parkinson’s Disease (PD) treated with continuous subcutaneous foslevodopa/foscarbidopa infusion in routine clinical practice.
Background: Continuous subcutaneous foslevodopa/foscarbidopa infusion (LDp/CDp) is a recently introduced device-aided therapy for advanced PD with motor fluctuations. Clinical trials demonstrated significant reductions in OFF time and increases in ON time without troublesome dyskinesia; however, real-world data on dosing strategies and tolerability remain limited.
Method: We conducted a retrospective observational study including patients with advanced PD initiated on foslevodopa/foscarbidopa continuous subcutaneous infusion at single academic neurology center. Demographic data, infusion parameter (base rate, small and large rates, extra doses, and loading dose), and adverse events were extracted from clinical records. Descriptive statistics were used to summarize patient characteristics and treatment parameters.
Results: Twenty-eight patients with advanced PD were included. Mean age was 68.8 ± 10.3 years (range 45-85). The mean base infusion rate was 0.35 ± 0.10 mL/h, with substantial inter-individual variability (range 0.19-0.61 mL/h) and slightly higher values compared with the 0.32 mL/h rate suggested by conversion algorithms. Mean small and large infusion rates were 0.20 ± 0.04 mL/h and 0.38 ± 0.10 mL/h, respectively. The mean extra dose administered was 0.15 ± 0.04mL/h, while the mean loading dose was 1.02 ± 0.30 mL. Adverse events occurred in 20 patients (71.4%), most commonly infusion-site nodules and erythema. No severe systemic complications were observed.
Conclusion: In this real-world cohort of patients with advanced PD, continuous subcutaneous foslevodopa/foscabidopa infusion was feasible and generally well tolerated. The wide variability in infusion rates and the tendency toward higher doses than recommended algorithms highlight the need for individualized dose titration in routine clinical practice.
To cite this abstract in AMA style:
I. Murasan, R. Margarit, R. Radu, L. Ungureanu, S. Berzunteanu, A. Drujescu, D. Batrinu, R. Chiujdea, R. Ilea, S. Diaconu, C. Falup-Pecurariu. Real-world variability in dosing of continuous subcutaneous foslevodopa/foscarbidopa infusion in advanced Parkinson’s disease: evidence from a single-center cohort [abstract]. Mov Disord. 2026; 41 (suppl 1). https://www.mdsabstracts.org/abstract/real-world-variability-in-dosing-of-continuous-subcutaneous-foslevodopa-foscarbidopa-infusion-in-advanced-parkinsons-disease-evidence-from-a-single-center-cohort/. Accessed October 1, 2026.« Back to 2026 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/real-world-variability-in-dosing-of-continuous-subcutaneous-foslevodopa-foscarbidopa-infusion-in-advanced-parkinsons-disease-evidence-from-a-single-center-cohort/